Lead Product(s) : JBI-802
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JBI-802 Phase I Data Suggests Potential in Immunotherapy-Resistant Tumors
Details : JBI-802 is a first-in-class CoREST inhibitor with dual action on LSD1 and HDAC6, undergoing phase 1/2 trials for essential thrombocythemia and related neoplasms.
Product Name : JBI-802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : JBI-802
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HMB-001
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $135.0 million
Deal Type : Series B Financing
Details : The Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline ...
Product Name : HMB-001
Product Type : Antibody
Upfront Cash : Undisclosed
February 20, 2023
Lead Product(s) : HMB-001
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Deep Track Capital
Deal Size : $135.0 million
Deal Type : Series B Financing
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA offers CRISPR, Vertex drug program VIP status for its comeback play
Details : CTX001 has received Orphan Drug Designation from the U.S. FDA for transfusion-dependent beta thalassemia and from the EMA for sickle cell disease and transfusion-dependent beta thalassemia .
Product Name : CTX001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SP-420
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PK data confirmed that the doses of SP-420 planned for the company's upcoming Phase 1-2 trial in patients with transfusional iron overload (TIO) should provide sufficient drug exposure for the desired therapeutic effect.
Product Name : SP-420
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : SP-420
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable